Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorSantos Vivas, Cristina
dc.contributor.authorLa Casta, Adelaida
dc.contributor.authorGarcía-Alfonso, Pilar
dc.contributor.authorJimenez Fonseca, Paula
dc.contributor.authorSoto Alsar, Javier
dc.contributor.authorBaraibar, Iosune
dc.date.accessioned2025-09-16T10:38:36Z
dc.date.available2025-09-16T10:38:36Z
dc.date.issued2025-08
dc.identifier.citationGarcía-Alfonso P, Jimenez-Fonseca P, Soto-Alsar J, Baraibar I, Santos C, La Casta A, et al. Three-year survival follow-up of patients with gastrointestinal cancer treated during the COVID-19 pandemic in Spain: data from the PANDORA-TTD20 study. Oncologist. 2025 Aug;30(8):oyae300.
dc.identifier.issn1549-490X
dc.identifier.urihttp://hdl.handle.net/11351/13657
dc.descriptionCoronavirus disease; Gastrointestinal cancer; Spatial frailties
dc.description.abstractIntroduction The initial SARS-CoV-2 pandemic wave in Spain in 2020 precipitated significant paradigm shifts in gastrointestinal oncology patient management. This study captures the “Zeitgeist” of this period by analyzing adaptive strategies, treatment modifications, and survival outcomes, leveraging a 3-year follow-up perspective to extract insights from this unprecedented experience. Methods We conducted a multicenter, retrospective cohort study utilizing the RETUD-TTD registry, encompassing 703 patients across 19 Spanish centers in April 2020. We evaluated alterations in clinical practice, therapeutic approaches, coronavirus disease 2019 (COVID-19)-related impacts, and patient survival. A Bayesian hierarchical model was employed to identify potential regional-specific frailties. Results The peak of the pandemic in April 2020 catalyzed substantial shifts in oncological care delivery. Outpatient consultations decreased by 13%, with a notable selection bias toward cases with more favorable prognostic indicators. Multidisciplinary tumor board discussions were significantly curtailed (eg, mean monthly colorectal cancer cases discussed was reduced from 40 to 23), compromising qualitative care measures. This occurred concurrently with an average of over 3 oncologists per center on medical leave. Contrary to initial concerns, the healthcare system demonstrated remarkable resilience. The majority of patients received standard-of-care therapies with regulatory approval, albeit with regimen modifications in 15% of cases. These adaptations included extended dosing intervals, dose intensity modulations, and transitions to oral formulations while maintaining unexpectedly stable long-term survival outcomes. The Bayesian frailty model detected minimal unmeasured prognostic factors related to geographic location, and the type of pandemic-induced adaptation did not significantly impact survival. The model revealed that coronavirus disease 2019’s impact was less pronounced than other core prognostic variables. Conclusions The decentralized Spanish healthcare system exhibited substantial robustness in managing pre-pandemic diagnosed gastrointestinal malignancies, despite asymmetrical, and occasionally severe organizational disruptions. The insights gleaned from this experience could inform future crisis preparedness strategies and optimize care provision during subsequent public health emergencies.
dc.language.isoeng
dc.publisherOxford University Press
dc.relation.ispartofseriesThe Oncologist;30(8)
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectPandèmia de COVID-19, 2020-
dc.subjectRegistres hospitalaris
dc.subjectEstadística bayesiana
dc.subjectAparell digestiu - Càncer - Tractament
dc.subject.meshPandemics
dc.subject.meshCoronavirus Infections
dc.subject.meshRegistries
dc.subject.meshGastrointestinal Neoplasms
dc.subject.mesh/therapy
dc.subject.meshBayes Theorem
dc.titleThree-year survival follow-up of patients with gastrointestinal cancer treated during the COVID-19 pandemic in Spain: data from the PANDORA-TTD20 study
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1093/oncolo/oyae300
dc.subject.decspandemias
dc.subject.decsinfecciones por Coronavirus
dc.subject.decsregistros
dc.subject.decsneoplasias gastrointestinales
dc.subject.decs/terapia
dc.subject.decsteorema de Bayes
dc.relation.publishversionhttps://doi.org/10.1093/oncolo/oyae300
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[García-Alfonso P, Soto-Alsar J] Medical Oncology Department, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Universidad Complutense, Madrid, Spain. [Jimenez-Fonseca P] Medical Oncology Department, Hospital Universitario Central de Asturias (HUCA), Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain. [Baraibar I] Medical Oncology Department, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Santos C] Medical Oncology Department, Institut Català d’Oncologia (ICO), Translational Research Laboratory, ICO-Bellvitge Biomedical Research Institute (IDIBELL)-CIBERONC, Barcelona, Spain. [La Casta A] Medical Oncology Department, Hospital Universitario de Donostia, Guipúzcoa, Spain
dc.identifier.pmid39550209
dc.identifier.wos001356276900001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record